Edwards Lifesciences Corp
EW
View Detailed Chart
83.380USD
+0.300+0.36%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
48.42BMarket Cap
35.51P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.36%
5 Days
-1.11%
1 Month
-3.38%
6 Months
+10.95%
Year to Date
+12.63%
1 Year
+13.72%
View Detailed Chart
TradingKey Stock Score of Edwards Lifesciences Corp
Currency: USD Updated: 2025-12-12Key Insights
Edwards Lifesciences Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 17/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 94.75.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Edwards Lifesciences Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
34
analysts
Buy
Current Rating
94.747
Target Price
+12.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Edwards Lifesciences Corp Highlights
StrengthsRisks
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 5.44B.
Overvalued
The company’s latest PE is 35.38, at a high 3-year percentile range.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 7.64K shares of this stock.
Edwards Lifesciences Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Edwards Lifesciences Corp Info
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Ticker SymbolEW
CompanyEdwards Lifesciences Corp
CEOZovighian (Bernard J)
Websitehttps://www.edwards.com
FAQs
What is the current price of Edwards Lifesciences Corp (EW)?
The current price of Edwards Lifesciences Corp (EW) is 83.380.
What is the symbol of Edwards Lifesciences Corp?
The ticker symbol of Edwards Lifesciences Corp is EW.
What is the 52-week high of Edwards Lifesciences Corp?
The 52-week high of Edwards Lifesciences Corp is 87.890.
What is the 52-week low of Edwards Lifesciences Corp?
The 52-week low of Edwards Lifesciences Corp is 65.940.
What is the market capitalization of Edwards Lifesciences Corp?
The market capitalization of Edwards Lifesciences Corp is 48.42B.
What is the net income of Edwards Lifesciences Corp?
The net income of Edwards Lifesciences Corp is 4.17B.
Is Edwards Lifesciences Corp (EW) currently rated as Buy, Hold, or Sell?
According to analysts, Edwards Lifesciences Corp (EW) has an overall rating of Buy, with a price target of 94.747.
What is the Earnings Per Share (EPS TTM) of Edwards Lifesciences Corp (EW)?
The Earnings Per Share (EPS TTM) of Edwards Lifesciences Corp (EW) is 2.348.
Related Instruments
-0.22%
+2.40%
+0.63%
+3.17%
+0.97%
-0.42%
+0.34%
-1.30%
-1.61%
+0.34%
+0.45%
+0.89%
+1.25%
-0.40%
-0.52%
+0.66%
+0.49%
+0.58%
+0.32%
